Navigation Links
Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
Date:9/5/2007

Patient Forecast Projects Significant Expansion of Drug-Treated Population, But Only For a Limited Time Due to a Cohort Effect, According to a New

Report from Decision Resources

WALTHAM, Mass., Sept. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, has found that a significant proportion of hepatitis C virus (HCV) patients do not achieve a sustained virologic response or are not able to tolerate current first-line treatment. According to the new report entitled Hepatitis C Virus Patient Flow Model and Treatment Algorithm, although currently available therapies can cure HCV, these agents are effective in only about half of all patients who receive therapy. The lack of available efficacious second- and third-line therapies leads to the accumulation of patients who are non-responsive to first-line therapy. Because HCV is not a highly fatal disease, this growing population is awaiting the launch of novel therapies and represents an important segment in the HCV market.

Hepatitis C virus represents a large commercial opportunity for drug developers due to its high prevalence, the relatively poor efficacy and side effects of current therapies and its large undiagnosed and under treated population.

"A sizeable cohort of the HCV-infected patients is aging, developing progressive liver disease, and is awaiting the introduction of several innovative new therapies in late-stage development," said John Lebbos, M.D., therapeutic area director at Decision Resources. "However, over the longer term, the size of the candidate population for treatment will be limited due to the dramatic decreases in the incidence of HCV that have been achieved as well as the improved efficacy of novel agents."

Based on this report, Decision Resources is offering an exclusive, in- depth webinar entitled Hepatitis C Virus: Forecasting the Drug-Treated and Treatment Eligible Populations from 2006 to 2021. The webinar, presented by Dr. Lebbos, will be held at 10 AM (EDT) on September 25, 2007. To register, visit http://www.DecisionResources.com.

About Hepatitis C Virus Patient Flow Model and Treatment Algorithm

This specialized report includes a detailed, annualized patient forecast model of the HCV population from 2006 to 2021 which includes the incidence- and mortality-based model includes estimates of the number of patients eligible for first-, second-, third, and fourth-line treatment by genotype and the impact of novel, more effective therapies on the epidemic and treatment- eligible populations. The HCV patient flow model also allows the user to adjust key assumptions, providing the model with flexibility to model different scenarios.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Scorecard to help in diabetic risk assessment of the Indian Population
3. Increasing risk of heart failure for ageing population
4. Prime Minister Manmohan Against Incentive-Based Population Control
5. Pigs Population A Major Threat To Encephalitis Ravaged UP
6. Scorecard to help in diabetic risk assessment of the Indian Population
7. Elderly Population’s Sedentary Lifestyle Is Dependant On Their Expectations From Lif
8. Rural Population Enjoys Better Mental Health
9. Prevention And Control Of Diabetes Crucial To Indian Population
10. World population To Be Seven billion in Six Years
11. Inclination of North Carolina’s Elderly Population towards Home Remedie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology: